|

Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer

RECRUITINGSponsored by Hunan Province Tumor Hospital
Actively Recruiting
SponsorHunan Province Tumor Hospital
Started2021-10-03
Est. completion2026-09-15
Eligibility
Age18 Years+
View on ClinicalTrials.gov →

NCT05059951

Summary

Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.

Eligibility

Age: 18 Years+
Inclusion Criteria:

1. ≥18，Lung Cancer Confirmed by Histopathology
2. Treated with Chemotherapy with or Without Checkpoint Inhibitors.
3. ECOG 0 - 1.
4. Predicted survival ≥ 12 weeks.
5. Adequate bone marrow hematopoiesis and organ function
6. Presence of measurable lesions according to RECIST 1.1.
7. Subjects with stable brain metastases may be included in the study.

Exclusion Criteria:

Patients did not match for the Inclusion Criteria.

Conditions3

CancerLung CancerNon Small Cell Lung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.